14
Participants
Start Date
March 28, 2021
Primary Completion Date
August 4, 2021
Study Completion Date
September 3, 2021
acoramidis
Quotient Sciences, Ruddington
Eidos Therapeutics, a BridgeBio company
INDUSTRY